Assessment of erythema or telangiectasia ‐ not measured · Participants with ocular rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Assessment of erythema or telangiectasia · Participants with rosacea
Clindamycin phosphate 1.2% + tretinoin 0.025% gel showed no clear difference in assessment of erythema or telangiectasia compared with placebo (moderate certainty).
1 finding from 1 review
Assessment of erythema or telangiectasia · Participants with rosacea
1 finding from 1 review
Physician‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Assessment of erythema or telangiectasia · Participants with rosacea
1 finding from 1 review
Assessment of erythema or telangiectasia ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Physician‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Assessment of erythema or telangiectasia · Participants with rosacea
1 finding from 1 review
Failure to achieve complete resolution Clinical assessment · patients with seborrhoeic dermatitis
Ketoconazole may leads to lower failure to achieve complete resolution Clinical assessment compared with placebo (low certainty).
1 finding from 1 review
Failure to achieve complete resolution (combined for face and scalp) Clinical assessment · patients with seborrhoeic dermatitis
Ketoconazole showed no clear difference in failure to achieve complete resolution (combined for face and scalp)… compared with steroids (low certainty).
1 finding from 1 review
Failure to achieve complete resolution (long term, combined for face and scalp) Clinical assessment · patients with seborrhoeic dermatitis
1 finding from 1 review
Failure to achieve complete resolution ‐ Face only Clinical assessment · patients with seborrhoeic dermatitis
Ketoconazole showed no clear difference in failure to achieve complete resolution ‐ Face only Clinical assessment compared with ciclopirox (low certainty).
1 finding from 1 review
Failure to achieve complete resolution (long term) ‐ Face only Clinical assessment · patients with seborrhoeic dermatitis
Ketoconazole showed no clear difference in failure to achieve complete resolution (long term) ‐ Face only… compared with ciclopirox (low certainty).
1 finding from 1 review
Failure to achieve complete resolution (combined for face and scalp) Clinical assessment · patients with seborrhoeic dermatitis
Ciclopirox probably leads to lower failure to achieve complete resolution (combined for face and scalp)… compared with placebo (moderate certainty).
1 finding from 1 review
Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.1% probably leads to higher physician's assessment of global response of improvement, clear or… compared with corticosteroids (moderate certainty).
3 findings from 1 review
RR 3.09 [2.14, 4.45]
1 study · 371 participants
Moderate
RR 0.95 [0.78, 1.16]
1 study · 377 participants
Low
RR 1.32 [1.17, 1.49]
1 study · 972 participants
Moderate
Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.03% probably leads to higher physician's assessment of global response of improvement, clear or… compared with corticosteroids (moderate certainty).
4 findings from 1 review
RR 2.05 [1.36, 3.08]
1 study · 411 participants
Moderate
RR 2.58 [1.96, 3.38]
2 studies · 790 participants
Moderate
RR 0.45 [0.13, 1.57]
2 studies · 409 participants
Very low
Show 1 more finding
Participant's self‐assessment of global response of improvement: tacrolimus 0.03% 2x/day versus hydrocortisone acetate 1% 2x/day · people with atopic dermatitis
Tacrolimus 0.03% probably leads to higher participant's self‐assessment of global response of improvement:… compared with corticosteroids (moderate certainty).
1 finding from 1 review
Physician's assessment of global response of improvement · people with atopic dermatitis
Tacrolimus 0.03% leads to lower physician's assessment of global response of improvement, clear or… compared with tacrolimus 0.1% (high certainty).
1 finding from 1 review
Physician's assessment of global response of improvement · people with atopic dermatitis
Tacrolimus 0.03% may leads to higher physician's assessment of global response of improvement compared with pimecrolimus 1% (low certainty).
1 finding from 1 review
Participant's self‐assessment of global response of improvement · people with atopic dermatitis
Tacrolimus 0.1% may leads to higher participant's self‐assessment of global response of improvement compared with corticosteroids (low certainty).
1 finding from 1 review